Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
BROG Brooge Holdings Ltd
EMRAF Emera Inc
PG Procter & Gamble Co
CLOU Global X Cloud Computing ETF Global X Cloud Computing ETF
GDRX Goodrx Holdings Inc
O Realty Income Corp

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.


Last Trade
0.27 (0.19%)
B/A Size

Market Hours

Closing Price
Day's Change
0.68 (0.47%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Tesla is a 'must own' stock, says Wall Street analyst who returns to bullish stance after start-of-year downgrade

4:21 am ET October 22, 2020 (MarketWatch)

By Barbara Kollmeyer

'We were too early on our downgrade,' admit Baird analysts

It isn't too late to "join the party."

That's according to analysts at Baird, who on Thursday upgraded shares of Tesla (TSLA) to outperform and lifted their price target to $488. The electric-car maker late Wednesday reported a fifth straight quarter of profit and sales ( that climbed 40%. Chief Executive Officer Elon Musk described the July-September period as Tesla's "best quarter in history."

In a note to clients, Baird analysts Ben Kallo and David Katter admitted they were "too early" in downgrading the stock to a neutral rating ( January, after a longtime bullish position. At the time, they suggested it was time to cash in on gains. Tesla shares have soared over 405% so far this year.

Here's their mea culpa: "Clearly incorrect, we are now upgrading share as we think TSLA has the substantial access and ability to deploy capital, and has multiple ways to drive substantial revenue growth."

But better late than never on that upgrade, they suggest. "Tesla's competitive moat over peers is substantial (and growing, enabled buy rapid capital deployment) and we think it is unlikely traditional OEMs [original equipment manufacturers] will be able to effectively compete over time," said Baird analysts.

"We view Tesla as a 'must own' stock for investors looking for exposure to ESG, sustainability and disruptive technology trends," they added.

Kallo and Katter recently upgraded their price target ( to $450 from $360, ahead of the latest nudge higher.

Opinion:Tesla plays smoke and mirrors with profits again (

Elsewhere, Dan Ives at Wedbush left his own neutral rating on Tesla intact, in a note that was released ahead of the earnings call. What's important, said Ives, was the fact that Tesla "reiterated its goal of 500,000 vehicles for the year."

Ives noted that Tesla's cash from operations was $2.4 billion, ahead of their own estimates. "This sustained level of profitability is key for the bulls and speaks to a business model which is staying out of the red ink despite this unprecedented COVID-19 dark storm," he said.

-Barbara Kollmeyer; 415-439-6400;

(END) Dow Jones Newswires

October 22, 2020 04:21 ET (08:21 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.